|
Press Release- 2015
Ness Ziona, June 22nd 2015. Vaxil reports today that its lead product, ImMucin, has been granted an “orphan drug” designation by the US Food and Drug Administration (FDA), for the treatment of multiple myeloma (MM).
For further details see the attached PDF file.
Ness Ziona, March 16th 2015. Vaxil reports that its lead product, ImMucin has received orphan drug designation from the European Medicines Agency (EMA) of the European Commission (EC) for the treatment of Multiple Myeloma.
For further details see the attached PDF file.
beck to top
|
|
